All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cultural Competency and Respect Are Crucial for Addressing Disparities in Cancer Care

April 23rd 2025

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

BCB-276 Earns FDA Breakthrough Therapy Nod for Pediatric Diffuse Intrinsic Pontine Glioma

April 23rd 2025

The FDA granted breakthrough therapy designation to BCB-276 for pediatric diffuse intrinsic pontine glioma.

First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC

April 23rd 2025

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC

April 23rd 2025

Fawzi F Abu Rous, MD, discusses updates to the ASCO Living Guidelines for the management of stage IV non–small cell lung cancer with driver alterations.

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

April 23rd 2025

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Mutational Sequencing Evolutions Drive Precision Medicine Approaches for AML

April 22nd 2025

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

PSMA PET Guides the Individualized Use of Lutetium-Based Therapies in mCRPC

April 22nd 2025

Evan Y. Yu, MD, discusses the clinical evolution of radiopharmaceuticals for patients with mCRPC and how PSMA PET may evolve to monitor treatment response.

Responsible AI Use Ushers in a New Era of Oncology Practice and Patient Care

April 22nd 2025

Douglas Flora, MD, FACCC, LSSBB, discusses the growing role of artificial intelligence tools in oncology practice.

Fox Chase Cancer Center Physicians Open New Trial For Patients With Colorectal Cancer That Has Spread to the Liver

April 22nd 2025

Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a HAI pump along with standard chemotherapy.

Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS

April 22nd 2025

Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.

Health Canada Approves Pembrolizumab/Chemotherapy for Unresectable, Advanced or Metastatic Pleural Mesothelioma

April 22nd 2025

Pembrolizumab/chemotherapy was approved by Health Canada for the treatment of patients with unresectable advanced or metastatic pleural mesothelioma.

Oncodetect Test Is Now Available for MRD Detection in Solid Tumors

April 22nd 2025

The Oncodetect test is now available for use in molecular residual disease detection in patients with solid tumors.

Female Leadership and Representation in Oncology Is an Immense ‘Honor and Responsibility’

April 22nd 2025

Reshma Lillaney Mahtani, DO, highlights her experience as a leader in oncology and emphasizes the need to further uplift other women in the field.

Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma

April 22nd 2025

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer

April 21st 2025

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.

Fertility and Toxicity Considerations Factor into TNBC Management

April 21st 2025

Nerea Lopetegui-Lia, MD, discusses fertility preservation options for patients with TNBC and considerations for managing treatment-related toxicities.

Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, to Lead City of Hope’s Women’s Cancers Program

April 21st 2025

Hope S. Rugo, MD, has led key breast cancer therapy trials and exudes a passion for serving patients.

China’s NMPA Accepts sNDA for Repotrectinib for NTRK+ Solid Tumors

April 21st 2025

China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

April 21st 2025

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer

April 21st 2025

Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.